ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF.
| パッケージサイズ | 在庫状況 | 単価(税別) | ||
|---|---|---|---|---|
| 無料サンプル 1 mg | ||||
| 1 mg | 在庫あり | ￥ 16000 | ||
| 5 mg | 在庫あり | ￥ 23000 | ||
| 10 mg | 在庫あり | ￥ 42500 | ||
| 25 mg | 在庫あり | ￥ 91500 | ||
| 50 mg | 在庫あり | ￥ 180000 | ||
| 100 mg | 在庫あり | ￥ 269000 | ||
| 1 mL * 10 mM (in DMSO) | 在庫あり | ￥ 26500 | ||
| 説明 | ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF. |
| In vitro | ML228 represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications[1][2]. |
| In vivo | ML228 (injection; 1 µg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduces SCI secondary injury and promotes the recovery of neurological function[3]. |
| 別名 | ML228 |
| 分子量 | 415.5 |
| 分子式 | C27H21N5 |
| CAS No. | 1357171-62-0 |
Powder: -20°C for 3 years In solvent: -80°C for 2 years
DMSO: 30 mg/mL (72.2 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
引用文献
投与量変換You can also refer to dose conversion for different animals. 詳細
In vivo投与量計算 (透明溶液)計算器bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
